Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS)

Table 1 Demographic and longitudinal immunologic data for IRIS cases and matched controls

Characteristic*	Controls (n = 22)	Cases (n = 22)	p-value^±
Black race	22 (100)	22 (100)	0.99
Age (years), median (IQR)	38 (34, 47)	31 (29, 39)	0.02
Female sex	16 (73)	15 (68)	0.99
Duration since HIV diagnosis (months), median (IQR)	5.1 (2.7, 21.2)	2.7 (1.2, 26.8)	0.13
No. previous OI/HIV-related illnesses^‡
0	4 (18)	8 (36)	0.23
1	10 (45)	8 (36)
2	5 (23)	6 (28)
3	3 (14)	0(0)
TB status at ART initiation
No history of TB	10 (46)	15 (68)	0.26
Therapy completed before ART initiation	6 (27)	2 (9)
Therapy ongoing at ART initiation	6 (27)	5 (23)
Baseline immunovirologic data
CD4 cell count	79 (17, 140)	142 (67, 198)	0.02
CD4 cell percentage	7.0 (3.4, 9.0)	7.2 (4.6, 13.6)	0.51
HIV RNA, log₁₀ copies/ml	5.4 (4.6, 5.9)	5.4 (4.5, 5.9)	0.77
Immunovirologic data at IRIS diagnosis/control enrollment
CD4 cell count, cells/mm^3§	183 (66, 252)	263 (152, 337)	0.05
CD4 cell percentage	13.5 (10.4, 20)	14 (10.2, 20.4)	0.96
CD8 cell count, cells/mm³	578 (239, 1006)	875 (623, 1487)	0.02
CD8 cell percentage	55 (49, 57)	57 (50, 62)	0.15
CD4:CD8 cell ratio	0.28 (0.19, 0.39)	0.32 (0.14, 0.34)	0.64
HIV RNA, log₁₀ copies/ml	2.6 (2.6, 2.7)	2.6 (2.6, 2.6)	0.42
Immunovirologic data at 6 months
CD4 cell count, cells/mm^3§	161 (99, 294)	277 (158, 372)	0.10
CD4 cell percentage	13.9 (9.8, 20.7)	13.7 (10.2, 21.0)	0.96
HIV RNA, log₁₀ copies/ml	2.6 (1.6, 2.6)	2.3 (1.6, 2.6)	0.26

*Data are no. (%) of patients or medians (IQR), unless otherwise indicated. ^± p-values for comparison of case/control groups using Wilcoxon rank sum and Fisher's exact tests, where appropriate; <0.05 considered significant.
^‡As listed by the WHO (Reference number: WHO/HIV/2005.02). ^§Missing value for 1 IRIS case.

ISSN: 1742-6405